Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HK2 | P52789 | 5/20 | 0.34 |
| ▸ | HK1 | P19367 | 4/20 | 0.34 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705310 | 1.00 | KDM4E (0.37) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL24256228 | 1.00 | KDM4E (0.37) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL14426384 | 0.83 | KDM4E (0.35) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL18849204 | 0.77 | MAPK1 (0.48) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL31105669 | 0.77 | MAPK1 (0.48) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL20220892 | 0.76 | LMNA (0.38) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL24198606 | 0.71 | LRAT (0.37) | KDM4ELMNA | |
| SCHEMBL13746073 | 0.71 | LRAT (0.37) | KDM4ELMNA | |
| SCHEMBL14150479 | 0.71 | LRAT (0.37) | KDM4ELMNA | |
| SCHEMBL24265064 | 0.71 | LRAT (0.37) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4097138-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Avila Therapeutics, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115066438-A | ASGPR binding compounds for degrading extracellular proteins | 阿维拉治疗公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2021155317-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2021-08-05 | — | — | WO | disclosed |